| human | Q5 |
| P6178 | Dimensions author ID | 01050026227.63 |
| P496 | ORCID iD | 0000-0001-5918-6004 |
| P1153 | Scopus author ID | 37039664500 |
| P69 | educated at | Columbia University Mailman School of Public Health | Q5149896 |
| Wexner Medical Center at Ohio State University | Q7990266 | ||
| P108 | employer | NYU Langone Health | Q6956114 |
| P734 | family name | Oberstein | Q37037371 |
| P735 | given name | Paul | Q4925623 |
| Paul | Q4925623 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q58612678 | Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness |
| Q52778434 | Current and Emerging Therapies in Metastatic Pancreatic Cancer |
| Q89501490 | Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours |
| Q91116538 | Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes |
| Q46037965 | First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. |
| Q47324527 | HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. |
| Q91930617 | Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response |
| Q37993960 | Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature. |
| Q37898947 | Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. |
| Q41279772 | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. |
| Q36886497 | Pancreatic cancer: why is it so hard to treat? |
| Q37992446 | Pancreatic neuroendocrine tumors: entering a new era. |
| Q90243419 | Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines' |
| Q92281431 | Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) |
| Q35669138 | Safety and efficacy of everolimus in adult patients with neuroendocrine tumors |
| Q33896442 | Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma |
| Q38026449 | Update on novel therapies for pancreatic neuroendocrine tumors. |
| Q38026448 | Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors. |
| Q46053394 | Uptake and Patterns of Use of Gemcitabine for Metastatic Pancreatic Cancer: A Population-Based Study |
Search more.